Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EBITDA (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of EBITDA data on record, last reported at -$38.6 million in Q4 2025.

  • For Q4 2025, EBITDA rose 5.53% year-over-year to -$38.6 million; the TTM value through Dec 2025 reached -$106.3 million, up 25.0%, while the annual FY2025 figure was -$101.7 million, 21.86% up from the prior year.
  • EBITDA reached -$38.6 million in Q4 2025 per TNGX's latest filing, down from $15.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $15.9 million in Q3 2025 and bottomed at -$42.5 million in Q1 2025.
  • Average EBITDA over 5 years is -$25.8 million, with a median of -$27.9 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 958162.71% in 2021, then surged 148.28% in 2025.
  • A 5-year view of EBITDA shows it stood at -$22.8 million in 2021, then fell by 22.4% to -$27.9 million in 2022, then decreased by 7.12% to -$29.9 million in 2023, then plummeted by 36.84% to -$40.9 million in 2024, then grew by 5.53% to -$38.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$38.6 million in Q4 2025, $15.9 million in Q3 2025, and -$41.0 million in Q2 2025.